HSA-/PLGA-nanoparticles as diagnostic markers for hepatocellular carcinoma (HCC)
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. For curative treatment options, early diagnosis is crucial. In this context, the present invention provides a new contrast agent, made of Gd-DTPA-loaded HSA-/PLGA-nanoparticles for magnetic resonance imaging (MRI) enabling the detection of small HCC which are undetectable with current methods and improving differentiation between HCC and benign lesions in the cirrhotic lever.
Further Information: PDF
INNOVECTIS Gesellschaft für Innovations-Dienstleistungen mbH
Phone: +49 (0)69/2561632-0
Contact
Dr. Otmar Schöller
Media Contact
All latest news from the category: Technology Offerings
Newest articles
NTU and NUS spin-off cutting-edge quantum control technology
AQSolotl’s quantum controller is designed to be adaptable, scalable and cost-efficient. Quantum technology jointly developed at Nanyang Technological University, Singapore (NTU Singapore) and National University of Singapore (NUS) has now…
How Geothermal Energy Shapes Bavaria’s Green Future Through Sustainable Energy
The Bavarian State Ministry of Science and the Arts has extended its funding for the research association “Geothermal Alliance Bavaria,” with the University of Bayreuth (UBT) continuing as a member…
Spintronics memory innovation: A new perpendicular magnetized film
Long gone are the days where all our data could fit on a two-megabyte floppy disk. In today’s information-based society, the increasing volume of information being handled demands that we…